Vicore Pharma Holding AB (VCRE)

Biotechnology · market cap $4.6B · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-05-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vicore Pharma Holding AB (VCRE) is a Swedish biotechnology company with approximately 40 employees and a market capitalization of roughly $4.6 billion at the current share price of ~$11.44. Its pipeline centers on two assets: C21 in Phase 3 for COVID-19 and buloxibutid in Phase 2 for idiopathic pulmonary fibrosis (IPF). Financial details including cash, runway, and dilution history are not available in the provided data.

The catalyst path

2027-05-15 (est.)Phase 2 · Buloxibutidimp 7/10

Pipeline

Asset	Phase	Indication
Buloxibutid	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)
C21	Phase 3	COVID-19

Price & technical context

3-month

—

6-month

—

12-month

—

52-wk range

$9.51–$16.25

vs 50-day MA

-15.6%

vs 200-day MA

—

Realized vol

49.1%

Max drawdown

-41.5%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for VCRE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.